Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study.

Yarmus L, Akulian J, Wahidi M, Chen A, Steltz JP, Solomon SL, Yu D, Maldonado F, Cardenas-Garcia J, Molena D, Lee H, Vachani A; Interventional Pulmonary Outcomes Group (IPOG).

Chest. 2019 Nov 1. pii: S0012-3692(19)34119-4. doi: 10.1016/j.chest.2019.10.016. [Epub ahead of print]

PMID:
31678307
2.

Safely and Effectively Evaluating Computed Tomography-detected Lung Lesions. Much Work to Be Done.

Burks AC, Gould MK, Silvestri G, Yarmus LB, Sears CR, Arenberg DA, Gonzalez AV, Slatore CG, Tanner NT, Vachani A, Nana-Sinkam P, Fuster MM, Wahidi MM, Tanoue LT, Rivera MP.

Ann Am Thorac Soc. 2019 Nov;16(11):1360-1362. doi: 10.1513/AnnalsATS.201905-389PS. No abstract available.

PMID:
31437410
3.

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A.

J Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.

4.

Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation.

Berman AT, Jabbour SK, Vachani A, Robinson C, Choi JI, Mohindra P, Rengan R, Bradley J, Simone CB 2nd.

Transl Lung Cancer Res. 2019 Feb;8(1):5-14. doi: 10.21037/tlcr.2018.12.12. Review.

5.

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.

Thompson JC, Fan R, Black T, Yu GH, Savitch SL, Chien A, Yee SS, Sen M, Hwang WT, Katz SI, Feldman M, Vachani A, Carpenter EL.

Lung Cancer. 2019 Jan;127:25-33. doi: 10.1016/j.lungcan.2018.11.020. Epub 2018 Nov 19.

6.

A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.

Kossenkov AV, Qureshi R, Dawany NB, Wickramasinghe J, Liu Q, Majumdar RS, Chang C, Widura S, Kumar T, Horng WH, Konnisto E, Criner G, Tsay JJ, Pass H, Yendamuri S, Vachani A, Bauer T, Nam B, Rom WN, Showe MK, Showe LC.

Cancer Res. 2019 Jan 1;79(1):263-273. doi: 10.1158/0008-5472.CAN-18-2032. Epub 2018 Nov 28.

PMID:
30487137
7.

Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer.

Weng L, Guo L, Vachani A, Mesaros C, Blair IA.

Anal Chem. 2018 Jun 19;90(12):7552-7560. doi: 10.1021/acs.analchem.8b01175. Epub 2018 Jun 5.

8.

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, Schnall MD, Skinner CS, Tosteson ANA, Weaver DL, Vachani A, Mehta SJ, Rendle KA, Fedewa SA, Corley DA, Armstrong K.

CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30.

9.

Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team.

Chest. 2018 Sep;154(3):491-500. doi: 10.1016/j.chest.2018.02.012. Epub 2018 Mar 1.

10.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

11.

A doubly robust approach for cost-effectiveness estimation from observational data.

Li J, Vachani A, Epstein A, Mitra N.

Stat Methods Med Res. 2018 Oct;27(10):3126-3138. doi: 10.1177/0962280217693262. Epub 2017 Feb 27.

PMID:
29298637
12.

Mind the Gap: Addressing Provider-Level Barriers to Lung Cancer Screening.

Vachani A, Schapira MM.

Ann Am Thorac Soc. 2018 Jan;15(1):20-21. doi: 10.1513/AnnalsATS.201711-852ED. No abstract available.

PMID:
29286846
13.

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S.

Lung Cancer. 2017 Oct;112:118-125. doi: 10.1016/j.lungcan.2017.08.008. Epub 2017 Aug 12.

PMID:
29191584
14.

Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer.

Vachani A, Wong YN, Israelite J, Mitra N, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW, Epstein AJ.

Med Care. 2017 Dec;55(12):e131-e136. doi: 10.1097/MLR.0000000000000484.

PMID:
29135776
15.

On meta- and mega-analyses for gene-environment interactions.

Huang J, Liu Y, Vitale S, Penning TM, Whitehead AS, Blair IA, Vachani A, Clapper ML, Muscat JE, Lazarus P, Scheet P, Moore JH, Chen Y.

Genet Epidemiol. 2017 Dec;41(8):876-886. doi: 10.1002/gepi.22085. Epub 2017 Nov 7.

16.

Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement.

Kathuria H, Detterbeck FC, Fathi JT, Fennig K, Gould MK, Jolicoeur DG, Land SR, Massetti GM, Mazzone PJ, Silvestri GA, Slatore CG, Smith RA, Vachani A, Zeliadt SB, Wiener RS; ATS Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1202-1212. doi: 10.1164/rccm.201709-1858ST.

17.

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A, Wiener RS; ATS Assembly on Thoracic Oncology.

Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.

18.

Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Schonewolf CA, Verma V, Post CM, Berman AT, Frick MA, Vachani A, Lin C, Simone CB 2nd.

Lung Cancer. 2018 Mar;117:53-59. doi: 10.1016/j.lungcan.2017.07.005. Epub 2017 Jul 14.

PMID:
28800837
19.

Response.

Tanner NT, Porter A, Gould MK, Li XJ, Vachani A, Silvestri GA.

Chest. 2017 Aug;152(2):448-449. doi: 10.1016/j.chest.2017.03.043. No abstract available.

PMID:
28797390
20.

The Financial Implications of Lung Cancer Screening: Is It Worth It?

Shojaee S, Vachani A, Nana-Sinkam P.

J Thorac Oncol. 2017 Aug;12(8):1177-1179. doi: 10.1016/j.jtho.2017.06.016. No abstract available.

21.

Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.

Patnaik SK, Kannisto ED, Mallick R, Vachani A, Yendamuri S.

PLoS One. 2017 Jul 25;12(7):e0181926. doi: 10.1371/journal.pone.0181926. eCollection 2017.

22.

Whole-Genome Sequencing in Common Respiratory Diseases. Ready, Set, Go!

Hersh CP, Vachani A.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):121-122. doi: 10.1164/rccm.201703-0479ED. No abstract available.

23.

Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.

Xu R, Mesaros C, Weng L, Snyder NW, Vachani A, Blair IA, Hwang WT.

Biomark Med. 2017 Jul;11(7):547-556. doi: 10.2217/bmm-2017-0087. Epub 2017 May 23.

24.

AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.

Vachani A, Sequist LV, Spira A.

Am J Respir Crit Care Med. 2017 May 1;195(9):1150-1160. doi: 10.1164/rccm.201702-0433CI. Review.

25.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
26.

Erratum to: A Review of Shared Decision-Making and Patient Decision Aids in Radiation Oncology.

DemasWoodhouse K, Tremont K, Vachani A, Schapira MM, Vapiwala N, Simone CB 2nd, Berman AT.

J Cancer Educ. 2017 Jun;32(2):246. doi: 10.1007/s13187-017-1186-7. No abstract available.

PMID:
28191603
27.

A Review of Shared Decision-Making and Patient Decision Aids in Radiation Oncology.

Woodhouse KD, Tremont K, Vachani A, Schapira MM, Vapiwala N, Simone CB 2nd, Berman AT.

J Cancer Educ. 2017 Jun;32(2):238-245. doi: 10.1007/s13187-017-1169-8. Review. Erratum in: J Cancer Educ. 2017 Jun;32(2):246.

PMID:
28138917
28.

Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation.

Tanner NT, Porter A, Gould MK, Li XJ, Vachani A, Silvestri GA.

Chest. 2017 Aug;152(2):263-270. doi: 10.1016/j.chest.2017.01.018. Epub 2017 Jan 20.

29.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Bagley SJ, Vitale S, Zhang S, Aggarwal C, Evans TL, Alley EW, Cohen RB, Langer CJ, Blair IA, Vachani A, Whitehead AS.

Clin Lung Cancer. 2017 Mar;18(2):e143-e149. doi: 10.1016/j.cllc.2016.10.010. Epub 2016 Oct 26.

30.

Validation of highly sensitive simultaneous targeted and untargeted analysis of keto-steroids by Girard P derivatization and stable isotope dilution-liquid chromatography-high resolution mass spectrometry.

Frey AJ, Wang Q, Busch C, Feldman D, Bottalico L, Mesaros CA, Blair IA, Vachani A, Snyder NW.

Steroids. 2016 Dec;116:60-66. doi: 10.1016/j.steroids.2016.10.003. Epub 2016 Oct 13.

31.

Tobacco Control and Tobacco Cessation in Lung Cancer-Too Little, Too Late?

Stone E, Vachani A.

Semin Respir Crit Care Med. 2016 Oct;37(5):649-658. Epub 2016 Oct 12. Review.

PMID:
27732987
32.

How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision Making.

Schapira MM, Aggarwal C, Akers S, Aysola J, Imbert D, Langer C, Simone CB 2nd, Strittmatter E, Vachani A, Fraenkel L.

Ann Am Thorac Soc. 2016 Nov;13(11):1969-1976.

33.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

34.

Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population.

Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, Burdette L, Cai Q, Caporaso N, Chung CC, Gillanders EM, Haiman CA, Hansen HM, Henderson BE, Kolonel LN, Marchand LL, Li S, McNeill LH, Ryan BM, Schwartz AG, Sison JD, Spitz MR, Tucker M, Wenzlaff AS, Wiencke JK, Wilkens L, Wrensch MR, Wu X, Zheng W, Zhou W, Christiani D, Palmer JR, Penning TM, Rieber AG, Rosenberg L, Ruiz-Narvaez EA, Su L, Vachani A, Wei Y, Whitehead AS, Chanock SJ, Harris CC.

Lung Cancer. 2016 Aug;98:33-42. doi: 10.1016/j.lungcan.2016.05.008. Epub 2016 May 13.

35.

Recognizing the Many Faces of Chronic Obstructive Pulmonary Disease.

Castaldi PJ, Vachani A.

Am J Respir Crit Care Med. 2016 Jun 1;193(11):1190-2. doi: 10.1164/rccm.201601-0125ED. No abstract available.

36.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM.

Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.

37.

Screening for Lung Cancer. Improving Outcomes with Better Patient Selection.

Vachani A, Jett JR.

Am J Respir Crit Care Med. 2016 Mar 1;193(5):478-9. doi: 10.1164/rccm.201510-2096ED. No abstract available.

PMID:
26930429
38.

Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer.

Vachani A, Whitney DH, Parsons EC, Lenburg M, Ferguson JS, Silvestri GA, Spira A.

Chest. 2016 Jul;150(1):210-8. doi: 10.1016/j.chest.2016.02.636. Epub 2016 Feb 16.

39.

Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.

Veenstra CM, Vachani A, Ciunci CA, Zafar HM, Epstein AJ, Paulson EC.

J Am Coll Radiol. 2016 May;13(5):491-6. doi: 10.1016/j.jacr.2015.11.016. Epub 2016 Jan 14.

40.

Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.

Mazzone PJ, Wang XF, Lim S, Choi H, Jett J, Vachani A, Zhang Q, Beukemann M, Seeley M, Martino R, Rhodes P.

BMC Cancer. 2015 Dec 23;15:1001. doi: 10.1186/s12885-015-1996-0.

41.

Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.

Epstein AJ, Wong YN, Mitra N, Vachani A, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW.

J Clin Oncol. 2015 Dec 20;33(36):4259-67. doi: 10.1200/JCO.2015.61.9023. Epub 2015 Nov 23.

42.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.

Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711.

43.

An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, Mazzone PJ, Midthun DE, Napoli M, Ost DE, Powell CA, Rivera MP, Slatore CG, Tanner NT, Vachani A, Wisnivesky JP, Yoon SH; ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):881-91. doi: 10.1164/rccm.201508-1671ST.

44.

Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.

Vachani A, Hammoud Z, Springmeyer S, Cohen N, Nguyen D, Williamson C, Starnes S, Hunsucker S, Law S, Li XJ, Porter A, Kearney P.

Lung. 2015 Dec;193(6):1023-7. doi: 10.1007/s00408-015-9800-0. Epub 2015 Sep 16.

45.

Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study.

Tanner NT, Aggarwal J, Gould MK, Kearney P, Diette G, Vachani A, Fang KC, Silvestri GA.

Chest. 2015 Dec;148(6):1405-1414. doi: 10.1378/chest.15-0630.

46.

Trends in surveillance for resected colorectal cancer, 2001-2009.

Paulson EC, Veenstra CM, Vachani A, Ciunci CA, Epstein AJ.

Cancer. 2015 Oct 1;121(19):3525-33. doi: 10.1002/cncr.29469. Epub 2015 Jun 16.

47.

Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.

Mesaros C, Worth AJ, Snyder NW, Christofidou-Solomidou M, Vachani A, Albelda SM, Blair IA.

Bioanalysis. 2015;7(9):1157-73. doi: 10.4155/bio.15.53. Review.

48.

A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.

Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, Parsons E, Mitra N, Brody J, Lenburg ME, Spira A; AEGIS Study Team.

N Engl J Med. 2015 Jul 16;373(3):243-51. doi: 10.1056/NEJMoa1504601. Epub 2015 May 17.

49.

Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy.

Whitney DH, Elashoff MR, Porta-Smith K, Gower AC, Vachani A, Ferguson JS, Silvestri GA, Brody JS, Lenburg ME, Spira A.

BMC Med Genomics. 2015 May 6;8:18. doi: 10.1186/s12920-015-0091-3.

50.

Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry.

Wang Q, Rangiah K, Mesaros C, Snyder NW, Vachani A, Song H, Blair IA.

Steroids. 2015 Apr;96:140-52. doi: 10.1016/j.steroids.2015.01.014. Epub 2015 Jan 29.

Supplemental Content

Loading ...
Support Center